Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CVAX-02
- Development stage
- Preclinical
- Lead developer
- CastleVax
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intranasal
01
Overview
CVAX-02 (also referred to as the RSV + HMPV vaccine) is a bivalent, live attenuated, recombinant mucosal vaccine candidate developed by CastleVax for the prevention of Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (HMPV) infections. The vaccine utilizes a Newcastle Disease Virus (NDV) vector platform licensed from the Icahn School of Medicine at Mount Sinai, which is engineered to express the fusion (F) proteins of both RSV and HMPV. Administered via the intranasal route, CVAX-02 is designed to induce both local mucosal and systemic protective immunity. A key advantage of the NDV vector is the lack of pre-existing immunity to the virus in the human population, which supports its utility as a vaccine vector. The candidate is currently in preclinical development.
- Other names
- RSV + HMPV vaccineBivalent mucosal RSV+HMPV vaccine
02
Targets
RSV F (Respiratory syncytial virus fusion protein)HMPV F (Human metapneumovirus fusion protein)
Beyond the preview
Go deeper on CVAX-02.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CVAX-02.